Cargando…

Preliminary experience of oral fruquintinib-capecitabine as a new maintenance treatment strategy for advanced colorectal cancer in the era of coronavirus disease 2019 (COVID-19): case report and literature review

BACKGROUND: Bevacizumab combined with fluorouracil is the currently recommended maintenance treatment for metastatic colorectal cancer, but the use of bevacizumab needs to be carried out in hospitals, which invisibly increases the risk of patients’ exposure to coronavirus disease 2019 (COVID-19) dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quan, Ming, Chen, Zhiqin, Chen, Jingde, Hai, Yanan, Gao, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660051/ https://www.ncbi.nlm.nih.gov/pubmed/36388683 http://dx.doi.org/10.21037/jgo-22-824

Ejemplares similares

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer—a case report and literature review
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer
por: Nukatsuka, Mamoru, et al.
Publicado: (2023)

RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer
por: Wang, Kun, et al.
Publicado: (2023)

Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era
por: Dekker, Evelien, et al.
Publicado: (2020)

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
por: Zhang, Hong-Qiang, et al.
Publicado: (2022)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
por: Wang, Lei, et al.
Publicado: (2020)

Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
por: Qu, Fan-Jie, et al.
Publicado: (2023)

Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
por: Chen, Jianxin, et al.
Publicado: (2019)

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
por: Zhang, Ying, et al.
Publicado: (2019)

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study
por: Sun, Xue‐Song, et al.
Publicado: (2020)

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN
por: Chong, Xiaodan, et al.
Publicado: (2022)

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
por: Su, Jinsong, et al.
Publicado: (2019)

Case report: PRES associated with fruquintinib in a patient with metastatic colon cancer
por: Wang, Lu, et al.
Publicado: (2023)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
por: Shi, Min, et al.
Publicado: (2020)

Electrophysiology in the Era of Coronavirus Disease 2019
por: Kanthasamy, Vijayabharathy, et al.
Publicado: (2020)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
por: Qin, Shukui, et al.
Publicado: (2021)

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study
por: Zhang, Weijie, et al.
Publicado: (2022)

Ileitis Secondary to Oral Capecitabine Treatment?
por: Radwan, Rami, et al.
Publicado: (2012)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience
por: Guo, Qiaojuan, et al.
Publicado: (2020)

Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report
por: Wang, Yi, et al.
Publicado: (2022)

Home Dialysis in the Coronavirus Disease 2019 Era
por: Yerram, Preethi, et al.
Publicado: (2020)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma
por: SAIF, MUHAMMAD WASIF, et al.
Publicado: (2014)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
por: Zhao, Wensi, et al.
Publicado: (2023)

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
por: Chi, Dongmei, et al.
Publicado: (2021)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Laparoscopy in the coronavirus disease 2019 (COVID-19) era
por: Angioni, Stefano
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c483s7n4u02mrb4mdpa9jirn4b